Tag: bat

  • Reynolds American Files Final 6 PMTAs for Vuse Products

    Reynolds American Files Final 6 PMTAs for Vuse Products

    Reynolds American, a subsidiary of BAT, filed its final round of premarket tobacco product application (PMTA) submissions with the U.S. Food and Drug Administration (FDA) on Friday.

    The move will allow its Vuse and Velo brands to remain on the market in the United States for at least one year while the applications are reviewed. The process allows the FDA to evaluate whether the products should remain on the market as part of the FDA’s public health mission.

    The filing concludes an 11-month process for Reynolds which has the industry’s broadest portfolio of alternative nicotine products, according to a press release. Reynolds has filed six applications for its Vuse Solo, Vuse Ciro and Vuse Vibe vapor products, as well as for its Velo nicotine lozenge and modern oral pouch products. The Vuse Alto-branded device PMTA includes 12 cartridges in various flavors and nicotine strengths in menthol, two tobacco-flavored products and mixed berry.

    Across the six applications, over 530,000 pages of scientific data and more than 8,600 scientific documents have been submitted as part of the filings.

    “The U.S. is the world’s largest vaping market and so the completion of our PMTA filings is a really important step for us as we transform our organisation, drive a step change in our New Categories business, and increase our non-combustible consumer base and revenues. Our transformation is progressing very well and in the first six months of 2020 we attracted an additional 2.7million new non-combustible consumers compared to the same time last year,” Kingsley Wheaton, chief marketing officer for BAT said. “Globally, we now have nearly 12 million regular non-combustible consumers and the U.S. will play a large part of our ambition to grow this number to at least 50 million by 2030.”

  • Vuse,Vype Launch Vapor Subscription Service

    Vuse,Vype Launch Vapor Subscription Service

    vype

    Vuse and Vype, global e-cigarette brands, have launched a personalized subscription service for their adult consumers that allows ordering at the touch of a button. With a variety of plans to choose from, vapers can sign up for monthly deliveries that offer value, convenience and personalisation.

    In the United Kingdom, Vype has launched two monthly subscription services focusing on its award-winning pod mods the Vype ePen3 and Vype ePod. Vype ePen3 and Vype ePod won the e-cigarette category at 2019 and 2020 UK Product of the Year awards respectively.

    Each subscription plan includes a Vype ePen3 or Vype ePod every three months with a 25 percent saving on a three-month plan or a 33 percent saving on a six-month plan, both with no delivery charges. Each plan requires a minimum order of six packs per month.

    In the United States, Vuse continues to offer its popular Vuse Alto pod subscription service that includes a 10 percent discount on pods and free delivery.

  • BAT Working on Potential Covid-19 Vaccine

    BAT Working on Potential Covid-19 Vaccine

    British American Tobacco’s (BAT) U.S. bio-tech subsidiary, Kentucky BioProcessing (KBP), is developing a potential vaccine for Covid-19 and is now in pre-clinical testing.

    BAT hopes that if testing goes well, between 1 million and 3 million doses of the vaccine could be manufactured per week beginning in June. The work is intended to be carried out on a not-for-profit basis.

    The potential vaccine uses BAT’s proprietary, fast-growing tobacco plant technology, which is potentially safer than conventional vaccine production technology because tobacco plants can’t host pathogens that cause human disease. This technology is also faster because the elements of the vaccine accumulate in tobacco plants more quickly (six weeks in tobacco plants versus several months using conventional methods). The vaccine formulation also remains stable at room temperature unlike many conventional vaccines that require refrigeration. A single dose has the potential to deliver an effective immune response.

    In 2014, KBP was one of the few companies that created an effective treatment for Ebola, ZMapp, in conjunction with Mapp BioPharmaceuticals and the U.S. Biomedical Advanced Research and Development Authority.

    KBP was recently in headlines for cloning a portion of Covid-19’s genetic sequence, leading to the development of a potential antigen. The antigen was then inserted into tobacco plants for reproduction, purified once plants were harvested, and is now undergoing pre-clinical testing.

    BAT is exploring partnerships with government agencies to bring the vaccine to clinical studies as soon as possible. “We are engaged with the U.S. Food and Drug Administration and are seeking guidance on next steps,” said David O’Reilly, director of scientific research at BAT. “We have also engaged with the U.K.’s Department for Health and Social Care and BARDA in the U.S. to offer our support and access to our research with the aim of trying to expedite the development of a vaccine for Covid-19.

    “Vaccine development is challenging and complex work, but we believe we have made a significant breakthrough with our tobacco plant technology platform and stand ready to work with governments and all stakeholders to help win the war against Covid-19. We fully align with the United Nations’ plea for a whole-of-society approach to combat global problems,” he said.

  • Unrivaled Transformation

    Unrivaled Transformation

    Two leading tobacco companies present their most advanced next-generation products in the U.K.

    By George Gay

    Within the space of two weeks in February, British American Tobacco (BAT) and Philip Morris Limited (PM Limited) each held a launch party for their latest U.K.-market vapor products, and it seemed to me that there was something particularly significant about these events. Firstly, the products’ advanced technologies and contemporary aesthetics spoke volumes about the huge research, design and development efforts that have gone into producing and refining them.

    Secondly, the confidence displayed by the two companies seemed to speak volumes about their belief both in the products they were displaying and the rightness of the radical new directions their businesses are taking—from smoke to vapor. One of the panels of a static display at the PM event brought me up short. It was headed “The smoking problem.

    The industry has come a long way and, although no sensible person would argue that the journey from smoke to vapor has been easy, is nearly completed or will be smooth sailing from now on, these companies deserve credit for having been willing to publicly recognize that the products they have traditionally offered add up to a problem and to invest heavily in coming up with a solution, or at least, so far, a partial solution to that problem.

    In fact, it’s worth dwelling on that for a moment, I believe, because while the tobacco industry comes in for some well-deserved criticism, I cannot think of another consumer products industry that has undergone or is undergoing such a transformation. Of course, many will say that no other industry has such a toxic product to transform away from, but that’s not entirely true. Interviewed recently by The Guardian’s Amy Fleming, David Nutt, a professor and the director of the neuropsychopharmacology unit at Imperial College London, said that alcohol is so toxic it should be banned. Nutt has apparently invented a healthy synthetic alcohol, so it will be interesting to see whether the alcoholic beverage industry embraces it.

    Perhaps one day we will all be able to go down the pub for some guilt-free celebrations on synthetic alcohol and vapor. But in the meantime, at least the tobacco and nicotine industries have something to celebrate. Speaking at the company’s Feb. 13 launch event, BAT U.K.’s general manager, Gemma Webb, said the tobacco industry was entering the most dynamic period of change it had ever encountered. “We are experiencing an extraordinary, once-in-a-generation coming-together of societal change, public health awareness and, crucially, access to technological innovation in the nicotine category,” she said. “This convergence of factors has created a unique opportunity for the industry and our business: the opportunity to make a substantial leap forward in our ambition to provide our consumers with a choice of potentially reduced risk-tobacco and nicotine products.”

    The event included the launch of the newest iterations of BAT’s Vype electronic cigarettes, the Vype iSwitch and iSwitch Maxx, where much of the focus was on the introduction of the company’s Puretech vaping technology. Instead of the coil and wick that is traditionally associated with electronic cigarettes, Puretech incorporates an ultra-slim, stainless steel blade that heats the e-liquid to create vapor. “The blade, which is around the thickness of a human hair, has a surface area 10 times larger than a traditional coil and wick heating system,” BAT wrote in a press note that was handed out at the event. “The blade provides a much more precise and measured way to heat the e-liquid, increasing consumer taste satisfaction by ensuring a smoother, richer and more consistent vape, with no off-notes.” Puretech is being incorporated in both the Vype iSwitch and Vype iSwitch Maxx, the latter of which is said to be BAT’s most interactive and connected vapor device.

    And, of course, there is more development to come. Brief mention was made at the Feb. 13 launch event of BAT’s announce the day before that it had entered into a new global partnership with British automotive manufacturer McLaren that the company said was rooted in advanced technology and innovation. “The multiyear partnership is focused on accelerating its transforming tobacco agenda, at the heart of which is its commitment to providing a portfolio of potentially reduced-risk products (PRRPs), which can deliver a ‘better tomorrow’ for its consumers,” the press note said.

    OFF-NOTES

    This all sounds well and good, but it has to be acknowledged that not everybody is going to be celebrating. There are people within the tobacco control sector who, understandably, will look with disdain on the idea that the tobacco industry is once more in party mood when looking to the future. These people will be aware that the tobacco industry didn’t suddenly see the light, as some would have us believe. But the simple truth is that, switching smokers of combustible cigarettes from risky to less-risky products is proving to be one of those areas where the market is best at sorting things out, and that is because the interests of consumers and the interests of the marketers have been brought into alignment.

    The tobacco control community needs to accept that what the vapor side of the industry is doing is helping smokers. Certainly, the tobacco control sector should not try to pour cold water on the vapor movement by spreading lies and publishing unscientific papers just because it doesn’t like the tobacco industry, which seems to be happening. There are people opposed to tobacco who, by concentrating their fire on the vapor industry, are seemingly starting to forget that the original aim was to rid the world of cigarettes. They seem to be coming close to promoting combustible cigarettes.

    Fortunately, there are health experts who think differently. In March, it was left to Michael Siegel, a professor at the Boston University School of Public Health’s department of community health sciences, to point out that a proposed ban on e-cigarettes in San Francisco, California, USA, didn’t make a whole lot of sense when combustible cigarettes would remain on retailers’ shelves. Two San Francisco officials had introduced bills that would ban the sale of electronic cigarettes in the city until the U.S. Food and Drug Administration had evaluated their effect on public health. Siegel responded by pointing out that tobacco cigarettes have already had their safety tests and have failed miserably.

    He also questioned why the city didn’t take combustible cigarettes off the shelves. Of course, Siegel has been around long enough to know exactly why such cigarettes are not being taken off the shelves, but his question is interesting because it mirrors one often asked of tobacco manufacturers: Instead of trying to switch people to less-risky products, why don’t you stop selling combustible cigarettes? The answer is obvious. I mean, why don’t we dispense with the wheel to prevent people dying in automobile accidents as well as of pollution, which has overtaken smoking as a killer?

    The fact is that with most such endeavors, we have to stay focused on harm reduction rather than harm elimination, without dropping that as an ultimate goal. And in this respect, participants at the PM Limited event held on Feb. 26 were given the opportunity to listen to a presentation by Moira Gilchrist, vice president of scientific and public communications at Philip Morris International (PMI), about tobacco harm reduction and the part that PMI is playing in it by developing products underpinned by robust science and research.

    The presentation was part of the launch party for the company’s latest range of iQOS heated-tobacco and vapor products. IQOS products were displayed, and there were static presentations explaining, for instance, the timeline of product development from Accord to iIQOS, and why health problems stem from the inhalation of the byproducts of tobacco combustion.

    In a press note, PM Limited said that the three new smoke-free iQOS devices that were on display at the event are the company’s most advanced to date and have been designed to make it easy for smokers to switch away from combustible cigarettes completely. According to PM Limited’s managing director, Peter Nixon, the new products have been specifically designed to give every one of the U.K.’s 7.4 million smokers a way to stop “burning tobacco.” “We are confident that our new IiQOS range provides the solutions needed to help all U.K., smokers move away from cigarettes,” he said.

    One of the devices presented at the launch was the iQOS3, which was described as being the latest version of the tobacco-heating device and features a longer battery life, faster charging and a more ergonomic design. The iQOS Multi, meanwhile, was described as being a new, more compact tobacco-heating device that was designed to provide a different experience to that of PMI’s other devices. With iQOS Multi, consumers could use 10 back-to-back tobacco sticks before needing to charge the device.

    The iQOS Mesh, who first market is the U.K., was said to be a premium vapor product that uses a replaceable pod containing nicotine e-liquid. It, too, has replaced the traditional “coil and wick,” in this case with a mesh. The German-made mesh heater, which is 16 microns thick, is said to provide 1,332 tiny holes that allow e-liquid to flow and be heated evenly for a consistent vape experience every time. The heat control technology heats the e-liquid in less than 0.1 second after the user begins to puff on the device and applies precise heating cut-off to avoid liquid condensation. In addition, smart digital controls detect when e-liquid levels are low, thus avoiding overheating and a burnt taste.

    Picture of George Gay

    George Gay

  • BAT scientists propose new framework for assessing reduced-risk products

    Scientists at British American Tobacco (BAT) have proposed a new scientific framework that could be used to assess the reduced-risk potential of nicotine and tobacco products currently being developed.

    The new assessment framework employs a four-stage process that uses lab-based and clinical tests along with real-world observations of individual and population perception and use, according to BAT.

    “We propose that this assessment framework will help us build the required evidence base to demonstrate that novel tobacco and nicotine products can deliver a net population health gain in comparison to cigarette smoking,” Dr. James Murphy, head of reduced-risk substantiation at BAT told delegates at the Tobacco Science Research Conference (TSRC), in Naples, Florida, USA, in September.

    The first step in the process is the characterization of the product, which includes laboratory-based testing. This is followed by clinical testing to determine whether toxicant reductions measured in the laboratory are observed in consumers when the products are used. The third step is to determine what impact, if any, this reduction in toxicants will have on a person’s individual risk as well as the collective risk of the population using the products.

    According to BAT, in contrast to modified cigarettes, innovative new tobacco and nicotine products have significantly reduced toxicant levels.

    “We have observed reductions of 90 percent and more in the levels of certain toxicants present in these new tobacco and nicotine products and these are manifesting reductions when the aerosols are applied to in vitro tests, which can mimic some key disease processes and endpoints,” said Murphy. “These early-stage results demonstrate that in comparison to reduced toxicant prototype cigarettes, these new products have a greater potential to demonstrate disease relevant changes in humans—tests that we plan to do over the next 12-18 months.”